Glioblastoma is the most common, aggressive and deadly form of brain
cancer. Median overall survival for primary glioblastoma is 14.6
months with the standard treatments of surgery, radiation therapy and
the chemotherapy temozolomide, and falls to 5.5 – 11 months for
recurrent glioblastoma.
Tumor heterogeneity and the blood-brain barrier make it difficult to treat glioblastoma. Immunotherapies such as immune checkpoint inhibitors...
This is the second part of Cancer Frontline’s interview with Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology...
In October 2018, the Nobel Prize in Physiology or Medicine was awarded to Jim Allison, Ph.D., chair of Immunology, for his discoveries on...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million grant to evaluate innovative approaches to increase screening and prevention of cervical cancers in Mozambique, which has some of the highest rates of cervical cancer in the world.
The grant was awarded by the Partnerships for Enhanced Engagement in Research (PEER) program, sponsored by the U.S...
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to research the use of modified immune cells to fight...
DNA damage response (DDR) inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, are a type of targeted therapy used to treat...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...
An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they use...
In recent years, the surgical technique sentinel lymph node biopsy has allowed surgeons to more accurately determine how far cancer has spread...
Lymphomas are the most common hematological malignancy in the U.S., accounting for an estimated 80,000 new cancer diagnoses and 21,000 deaths...